

1 / 17



FIG. 1**MAS GL Scale at Rest****MAS GL Scale Dynamic**

FIG. 2




FIG. 3




FIG. 4




FIG. 5

		GM-1114-DP (N = 222)	Placebo (N = 75)
Preferred Term	Intensity	Subjects / Events	Subjects / Events
Headache	Total	5 (2.3%) / 5	0 / 0
	Mild	2 (0.9%) / 2	
	Moderate	3 (1.4%) / 3	
	Severe	0	
Eyelid Ptosis	Total	2 (0.9%) / 2	0 / 0
	Mild	2 (0.9%) / 2	
	Moderate	0	
	Severe	0	
Injection Site Bruising	Total	1 (0.5%) / 1	0 / 0
	Mild	1 (0.5%) / 1	
	Moderate	0	
	Severe	0	

N= number of subjects in safety population

There were no adverse events that lead to premature study discontinuation.

FIG. 6



FIG. 7




FIG. 8




FIG. 9

		QM-1114-IP (N = 230)	Placebo (N = 73)
Preferred Term	Intensity	Subjects / Events	Subjects / Events
Injection Site Bruising	Total	11 (4.8%) / 12	3 (4.1%) / 3
	Mild	11 (4.8%) / 12	2 (2.7%) / 2
	Moderate	0 / 0	1 (1.4%) / 1
	Severe	0 / 0	0 / 0
Injection Site Pain	Total	1 (0.4%) / 1	1 (1.4%) / 1
	Mild	1 (0.4%) / 1	1 (1.4%) / 1
	Moderate	0 / 0	0 / 0
	Severe	0 / 0	0 / 0
Headache	Total	1 (0.4%) / 1	1 (1.4%) / 1
	Mild	1 (0.4%) / 1	1 (1.4%) / 1
	Moderate	0 / 0	0 / 0
	Severe	0 / 0	0 / 0
Muscular weakness	Total	1 (0.4%) / 1	0 / 0
	Mild	1 (0.4%) / 1	0 / 0
	Moderate	0 / 0	0 / 0
	Severe	0 / 0	0 / 0

N= number of subjects in safety population

FIG. 10




FIG. 11




FIG. 12




FIG. 13





FIG. 14



	Daxi 40U SAKURA 1	Botox (BELMONT)	QM-1114-DP
Week 4/Day 30	97.5	92.9	96.4
Week 8/Day 60	91.5		92.9
Week 12/Day 90	84.1		73.7
Week 16/Day 120	71.1	31.7	53.7
Week 24/Day 150	35.4	11.9	23.6

10 / 17

FIG. 15




FIG. 16




FIG. 17




FIG. 18





FIG. 19



14 / 17

FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26

